Metabolic interaction between cancer cells and stromal cells according to breast cancer molecular subtype

Breast Cancer Research

Volumn 15, Issue 5, 2013, Pages

  Choi, Junjeong ^a   Kim, Do H ^b   Jung, Woo H ^b   Koo, Ja S ^b  

^a Yonsei University Wonju College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BECLIN 1; CARBONATE DEHYDRATASE IX; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLUCOSE TRANSPORTER 1; GLUTAMINASE; KI 67 ANTIGEN; LIGHT CHAIN 3 ALPHA; LIGHT CHAIN 3 BETA; MICROTUBULE ASSOCIATED PROTEIN 1; MONOCARBOXYLATE TRANSPORTER 4; PROGESTERONE; PROTEIN BNIP3; PROTEIN P62; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; UNCLASSIFIED DRUG; ESTROGEN RECEPTOR; MICROTUBULE ASSOCIATED PROTEIN 1 LIGHT CHAIN 3ALPHA; MICROTUBULE ASSOCIATED PROTEIN 1 LIGHT CHAIN 3BETA; PROGESTERONE RECEPTOR; SEQUESTOSOME 1; TUMOR MARKER; PROTEOME;

ADULT; ARTICLE; AUTOPHAGY; BREAST CANCER; CANCER CELL; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; GLYCOLYSIS; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MAJOR CLINICAL STUDY; PHENOTYPE; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STROMA CELL; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER; CANCER CLASSIFICATION; CELL INTERACTION; CELL METABOLISM; HISTOPATHOLOGY; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; MIDDLE AGED; MITOCHONDRION; MIXED TUMOR; NULL TYPE TUMOR; REVERSE WARBURG TYPE TUMOR; TUMOR CLASSIFICATION; UPREGULATION; WARBURG TYPE TUMOR; BREAST TUMOR; FEMALE; GENETICS; METABOLISM; METASTASIS; MORTALITY; PATHOLOGY;

ADULT; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; PHENOTYPE; PROTEOME; STROMAL CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 84883613147     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3472     Document Type: Article

References (25)

1. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314. 10.1126/science.123.3191.309, 13298683.
2. Bonuccelli G, Tsirigos A, Whitaker-Menezes D, Pavlides S, Pestell RG, Chiavarina B, Frank PG, Flomenberg N, Howell A, Martinez-Outschoorn UE, Sotgia F, Lisanti MP. Ketones and lactate " fuel" tumor growth and metastasis: evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle 2010, 9:3506-3514. 10.4161/cc.9.17.12731, 3047616, 20818174.
3. Martinez-Outschoorn UE, Balliet RM, Rivadeneira DB, Chiavarina B, Pavlides S, Wang C, Whitaker-Menezes D, Daumer KM, Lin Z, Witkiewicz AK, Flomenberg N, Howell A, Pestell RG, Knudsen ES, Sotgia F, Lisanti MP. Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: a new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle 2010, 9:3256-3276. 3041164, 20814239.
4. Pavlides S, Tsirigos A, Vera I, Flomenberg N, Frank PG, Casimiro MC, Wang C, Fortina P, Addya S, Pestell RG, Martinez-Outschoorn UE, Sotgia F, Lisanti MP. Loss of stromal caveolin-1 leads to oxidative stress, mimics hypoxia and drives inflammation in the tumor microenvironment, conferring the " reverse Warburg effect" : a transcriptional informatics analysis with validation. Cell Cycle 2010, 9:2201-2219. 10.4161/cc.9.11.11848, 20519932.
5. Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, Casimiro MC, Wang C, Fortina P, Addya S, Pestell RG, Martinez-Outschoorn UE, Sotgia F, Lisanti MP. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 2009, 8:3984-4001. 10.4161/cc.8.23.10238, 19923890.
6. Martinez-Outschoorn UE, Pavlides S, Whitaker-Menezes D, Daumer KM, Milliman JN, Chiavarina B, Migneco G, Witkiewicz AK, Martinez-Cantarin MP, Flomenberg N, Howell A, Pestell RG, Lisanti MP, Sotgia F. Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle 2010, 9:2423-2433. 10.4161/cc.9.12.12048, 20562526.
7. Martinez-Outschoorn UE, Trimmer C, Lin Z, Whitaker-Menezes D, Chiavarina B, Zhou J, Wang C, Pavlides S, Martinez-Cantarin MP, Capozza F, Witkiewicz AK, Flomenberg N, Howell A, Pestell RG, Caro J, Lisanti MP, Sotgia F. Autophagy in cancer associated fibroblasts promotes tumor cell survival: role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment. Cell Cycle 2010, 9:3515-3533. 10.4161/cc.9.17.12928, 3047617, 20855962.
8. Zu XL, Guppy M. Cancer metabolism: facts, fantasy, and fiction. Biochem Biophys Res Commun 2004, 313:459-465. 10.1016/j.bbrc.2003.11.136, 14697210.
9. Moreno-Sánchez R, Rodríguez-Enríquez S, Marín-Hernández A, Saavedra E. Energy metabolism in tumor cells. FEBS J 2007, 274:1393-1418. 10.1111/j.1742-4658.2007.05686.x, 17302740.
10. Kwon JE, Jung WH, Koo JS. Molecules involved in epithelial-mesenchymal transition and epithelial-stromal interaction in phyllodes tumors: implications for histologic grade and prognosis. Tumour Biol 2012, 33:787-798. 10.1007/s13277-011-0296-9, 22203494.
11. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
12. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
13. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410. 10.1111/j.1365-2559.1991.tb00229.x, 1757079.
14. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010, 28:2784-2795. 10.1200/JCO.2009.25.6529, 2881855, 20404251.
15. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF,. American Society of Clinical Oncology; College of American Pathologists American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145. American Society of Clinical Oncology; College of American Pathologists.
16. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ,. Panel members Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011, 22:1736-1747. 10.1093/annonc/mdr304, 3144634, 21709140, Panel members.
17. Bellot G, Garcia-Medina R, Gounon P, Chiche J, Roux D, Pouysségur J, Mazure NM. Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. Mol Cell Biol 2009, 29:2570-2581. 10.1128/MCB.00166-09, 2682037, 19273585.
18. Zhang H, Bosch-Marce M, Shimoda LA, Tan YS, Baek JH, Wesley JB, Gonzalez FJ, Semenza GL. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem 2008, 283:10892-10903. 10.1074/jbc.M800102200, 2447655, 18281291.
19. Pinheiro C, Sousa B, Albergaria A, Paredes J, Dufloth R, Vieira D, Schmitt F, Baltazar F. GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression. Histol Histopathol 2011, 26:1279-1286.
20. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology 2008, 52:108-118.
21. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000, 80:1943-1949. 10.1038/labinvest.3780204, 11140706.
22. Park SY, Kim KS, Lee TG, Park SS, Kim SM, Han W, Noh DY, Kim SW. The accuracy of preoperative core biopsy in determining histologic grade, hormone receptors, and human epidermal growth factor receptor 2 status in invasive breast cancer. Am J Surg 2009, 197:266-269. 10.1016/j.amjsurg.2007.11.024, 18614146.
23. Chen X, Yuan Y, Gu Z, Shen K. Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis. Breast Cancer Res Treat 2012, 134:957-967. 10.1007/s10549-012-1990-z, 22370627.
24. Badve SS, Baehner FL, Gray RP, Childs BH, Maddala T, Liu ML, Rowley SC, Shak S, Perez EA, Shulman LJ, Martino S, Davidson NE, Sledge GW, Goldstein LJ, Sparano JA. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol 2008, 26:2473-2481. 10.1200/JCO.2007.13.6424, 18487567.
25. Reddy JC, Reimann JD, Anderson SM, Klein PM. Concordance between central and local laboratory HER2 testing from a community-based clinical study. Clin Breast Cancer 2006, 7:153-157. 10.3816/CBC.2006.n.025, 16800975.